301.88

0.56% -1.51

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $301.88, with a volume of 84,022. It is down -0.56% in the last 24 hours and down -12.19% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Previous Close:

$303.39

Open:

$298.5

24h Volume:

84,022

Relative Volume:

0.19

Market Cap:

$8.41B

Revenue:

$7.46M

Net Income/Loss:

$-326.53M

P/E Ratio:

-22.56

EPS:

-13.3803

Net Cash Flow:

$-282.53M

1W Performance:

+17.27%

1M Performance:

-12.19%

6M Performance:

+9.41%

1Y Performance:

+624.66%

1-Day Range:

$296.36

$307.65

1-Week Range:

$259.08

$307.65

52-Week Range:

$37.19

$366.52

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1109)

Industry

Biotechnology (619)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

10,998

Twitter

Next Earnings Date

2026-08-03

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	301.73	7.87B	7.46M	-326.53M	-282.53M	-13.38
VRTX Vertex Pharmaceuticals Inc	468.44	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	616.55	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	926.70	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.39	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	170.88	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Raymond James	Strong Buy
Feb-24-26	Initiated	Wolfe Research	Outperform
Feb-02-26	Initiated	Wells Fargo	Equal Weight
Dec-15-25	Reiterated	Oppenheimer	Outperform
Nov-19-25	Initiated	BTIG Research	Buy
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

Jun 22, 2026

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen (PRAX-222) in Pediatric SCN2A-DEE Seizures - Minichart

Jun 22, 2026

FDA grants breakthrough therapy status to Praxis’ elsunersen - Investing.com UK

Jun 22, 2026

Praxis Precision Medicines receives FDA breakthrough therapy designation for elsunersen - Investing.com Canada

Jun 22, 2026

Form 8K Praxis Precision Medicines Inc For: 22 June By Investing.com - Investing.com Canada

Jun 22, 2026

FDA Breakthrough Therapy nod for Praxis (PRAX) seizure drug elsunersen - Stock Titan

Jun 22, 2026

Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results - Benzinga

Jun 22, 2026

Praxis Precision Medicines (PRAX) Receives FDA Breakthrough Ther - GuruFocus

Jun 22, 2026

Praxis Precision (PRAX) Receives FDA Breakthrough Designation fo - GuruFocus

Jun 22, 2026

Praxis Precision Medicines Potential Epilepsy Treatment Receives US FDA Breakthrough Therapy Designation - Moomoo

Jun 22, 2026

Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation - Yahoo Finance

Jun 22, 2026

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants - The Manila Times

Jun 22, 2026

Praxis Precision Medicines stock rises on FDA breakthrough status - Investing.com

Jun 22, 2026

FDA gives Praxis seizure drug Breakthrough Therapy status - Stock Titan

Jun 22, 2026

Jun 21, 2026

Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits

Jun 21, 2026

Jun 19, 2026

Precision Trading with Praxis Precision Medicines Inc. (PRAX) Risk Zones - Stock Traders Daily

Jun 19, 2026

Analysts Offer Insights on Healthcare Companies: Owlet (OWLT), Praxis Precision Medicines (PRAX) and Sarepta Therapeutics (SRPT) - The Globe and Mail

Jun 19, 2026

A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $162 to $1,201 - Moomoo

Jun 19, 2026

Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200 - Moomoo

Jun 19, 2026

Jun 18, 2026

Praxis Precision Medicines StockAnalyst consensus and trading snapshot - AD HOC NEWS

Jun 18, 2026

PRAX Initiates Coverage On RBC Capital -- Price Target Set at $4 - GuruFocus

Jun 18, 2026

Praxis a new outperform at RBC on recent pullback - MSN

Jun 18, 2026